Radiopharm Theranostics Limited (RADX)
NASDAQ: RADX · Real-Time Price · USD
4.280
-0.150 (-3.39%)
At close: Jul 20, 2026, 4:00 PM EDT
4.450
+0.170 (3.97%)
After-hours: Jul 20, 2026, 7:38 PM EDT

Radiopharm Theranostics Stock Forecast

Stock Price Forecast

According to 6 analysts polled by S&P Global, Radiopharm Theranostics stock has a consensus rating of "Strong Buy" and an average price target of $17.06. The average 1-year stock price forecast is 298.60% higher than the current stock price, while the lowest is $12.68 (+196.26%) and the highest is $30.15 (+604.44%).

Price Target: $17.06 (+298.60%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$12.68$17.06$15.37$30.15
Change+196.26%+298.60%+259.11%+604.44%
* Price targets were last updated on Jun 4, 2026.

Analyst Ratings

The average analyst rating for Radiopharm Theranostics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingJan '26Feb '26Mar '26Apr '26May '26Jun '26
Strong Buy333334
Buy111111
Hold000000
Sell000000
Strong Sell000000
Total444445

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
H.C. Wainwright
H.C. Wainwright
Buy
Initiates
$16
BuyInitiates$16+273.83%Jun 4, 2026
Maxim Group
Maxim Group
Buy
Maintains
$15
BuyMaintains$15+250.47%Mar 26, 2026
JonesTrading
JonesTrading
Buy
Reiterates
$30
BuyReiterates$30+600.93%Mar 25, 2026

Financial Forecast

Revenue This Year
4.76M
from 12.51M
Decreased by -61.99%
Revenue Next Year
5.24M
from 4.76M
Increased by 10.12%
EPS This Year
-0.03
from -0.06
EPS Next Year
-0.04
from -0.03
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingJun 30, 2021Jun 30, 2022Jun 30, 2023Jun 30, 2024Jun 30, 2025Jun 30, 2026
Revenue
--6.21M1.96M12.51M4.76M
Revenue Growth
----68.46%538.86%-61.99%
Operating Income
-1.16M-19.93M-28.59M-35.33M-35.13M-173.10M
Net Income
-1.16M-30.42M-34.61M-47.95M-38.34M-198.07M
EPS
-----0.06-0.03
Free Cash Flow
--31.35M-12.08M-12.04M-23.62M-156.56M
No. Analysts
-----4
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is AUD.

Revenue Forecast

Revenue202620272028
High10.5M
Avg4.8M
Lown/a

Revenue Growth

Revenue Growth202620272028
High
-16.5%
Avg
-62.0%
Low
-100.0%

EPS Forecast

EPS202620272028
High-0.03
Avg-0.03
Low-0.03

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-